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OBJECTIVES: Osteoarthritis (OA) is the most common musculoskeletal disease, with 
around 1.6 million patients in Spain. The aim of this study was to determine health 
care resource utilization and direct medical costs of patients suffering OA of the hip, 
knee and wrist in Spain in 2009. METHODS: A cost-of-illness analyses was performed 
to estimate direct medical costs of patients suffering OA. Prevalence data on OA by 
the Spanish Society of Rheumatology showed a value of 18% for the Spanish popula-
tion. a semi-structured questionnaire was sent to rheumatologists to collect data on 
health care resource utilization and costs. Inpatient costs were considered from the 
perspective of the public health care system. Direct medical costs included were 
ambulatory, diagnostic tests, physiotherapy, surgery, drug and administration costs. 
All costs referred to 2009. RESULTS: Patients diagnosed with OA of the hip, knee 
and wrist in Spain were estimated to be 1.6 million in 2009. Total medical costs for 
the Health Care System resulted as following: drug use 95c million, health care person-
nel 251c million, diagnostic tests 20c million, physiotherapy 93c million, surgery 105c 
million and adverse effects due to OA medication 25c million. Due to demographic 
changes and increasing prevalence, the number of patients is estimated to grow to 1.7 
million with total costs of 717c million in 2014. CONCLUSIONS: Direct medical 
costs for OA were estimated at 598c million for Spanish patients in 2009. Health care 
personnel represented 43% of the total direct medical costs. Aging of the population, 
development of new drugs and increasing patient expectations are likely to increase 
the future economic impact of OA, which remains a major public health burden.
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OBJECTIVES: To assess direct medical costs associated to hospital treatment of hip 
fractures in the elderly in a public hospital in Rio de Janeiro, Brazil and their association 
with demographic and clinical variables. METHODS: Observational, prospective study 
to assess resource utilization and direct medical costs associated to elderly hip fracture 
hospitalization in 2007 and 2008, under the health care provider perspective. a standard 
data collection instrument was used to register identiﬁ ed resources during prospective 
medical charts review. The resource utilization was converted into Brazilian Real (BRL), 
based on 2010 prices. Descriptive analysis of costs and resource utilization and their 
association with clinical and demographic variables were performed. RESULTS: Eighty 
two patients were included, 81.7% female, mean age of 76.96 years, hospitalization 
mean time of 12.66 days. Median total costs per patient were 3,064.76 BRL (IC95%: 
2,817.63–3,463.98). Clinical hospitalization and surgical procedure were responsible 
for 65.61% and 24.94% of costs, respectively. Median costs for patients submitted to 
surgical procedure until the fourth day of hospitalization were lower than median costs 
for patients submitted after the fourth day (2,136.45 BRL and 3,281.45 BRL, respec-
tively, P < 0.00001). A signiﬁ cant difference in average costs per type of surgical pro-
cedure was also observed. Variables sex, age over 80 years, fracture site and presence 
of cardiovascular disease were not associated with statistically signiﬁ cant differences in 
total costs. CONCLUSIONS: Clinical hospitalization and surgical procedure were the 
main cost components observed. Higher cost associated to inpatient treatment of hip 
fractures in patients who performed surgery after the fourth day of hospitalization added 
to available evidence about an increased risk of mortality after this period reinforce the 
need of priority establishment to treat elderly patients with hip fracture.
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OBJECTIVES: To examine annual direct medical & non-medical cost in large-scale 
rheumatoid arthritis (RA) patient cohort (IORRA) in Japan. METHODS: From 
patients’ perspective, we calculated direct medical (out-of-pocket costs to hospital & 
pharmacy and cost for complementary & alternative medicine(CAM)) and non-med-
ical costs (caregiving, transportation,self help devises, house modiﬁ cation) of RA 
patients, participants of the 15–17th IORRA Studies in Oct. 2007- Oct. 2008. We 
also assessed correlations between these costs and RA diseaseactivity, disability level 
and QOL. RESULTS: Data from 5204 RA patients were extracted. Annual direct 
medical costs were JPY132,000 (out-of-pocket to hospital, USD1 = JPY90), JPY84,000 
(out-of-pocket to pharmacy) and JPY 146,000 (CAM)), respectively. Annual direct 
non-medical costs were JPY105,000 (caregiving), JPY22,000 (transportation), 
JPY30,000 (self help devises) JPY188,000 (house modiﬁ cation), respectively. Consid-
ering utilization rates for each cost component (hospital/pharmacy: 100%, CAM: 
31.6%, caregiving: 10.5%, transportation: 100%, self help devices: 21.4%, house 
modiﬁ cation: 21.4%). We assumed that annual medical/non-medical cost per RA 
patient was JPY264,000 and JPY61,000, respectively. These costs increased progres-
sively with worsening RA diseaseactivity, disability level, or QOL. For example, 
patients with lower Eq-5D score (less than 0.5) spent more money than those with 
higher one (more than 0.8). Average medical and non-medical costs among them were 
JPY 30,802 vs. JPY17,887 and JPY229,519 vs. JPY19,536, respectively. CONCLU-
SIONS: Heavy economic burden lies in RApatients and grows heavier as the disease 
state is exacerbated using IORRA database. The results also suggest that the increase 
in medical/non-medical cost may be suppressed by proactively controlling RA.
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OBJECTIVES: Estimate the efﬁ ciency of Tumor Necrosis Factor α (TNFα) antagonists 
in moderate to severe rheumatoid arthritis (RA). METHODS: The analysis, performed 
from the Spanish Health Care System perspective, considers the annual cost of the drugs, 
and their efﬁ cacy, measured through the number needed to treat (NNT) to gain an 
additional patient who achieves ACR20, ACR50 and ACR70 response. Drug costs were 
obtained from a Spanish database. Data relative to efﬁ cacy was derived from a meta-
analysis, which evaluated the anti–TNFα drugs adalimumab (ADA), etanercept (ETA), 
and inﬂ iximab (INF). Efﬁ ciency was estimated in terms of incremental cost-efﬁ cacy 
ratios (ICER). RESULTS: Annual treatment cost per patient-year with ADA, ETA and 
INF is of 13.116c, 12.314c, and 14.047c, respectively. Applying the: 1) ACR20 criteria, 
the NNT with ADA, ETA, and INF were 4.2 (95% CI, 3.4–5.3), 6.5 (5.2–8.8), and 4, 
5(3.4–6.8), respectively; 2) the ACR50 criteria, the NNT with ADA, ETA, and INF were 
4.1 (3.4–5.1), 4.4 (3.7–5.5), and 6.6 (4.7–11.5), respectively; and 3) the ACR70 criteria, 
the NNT with ADA, ETA, and INF were 5.7 (4.6–7.5), 6.8 (5.3–9.4), and 8.6 (5.8–
16.7), respectively. The incremental annual cost per additional patient who achieves 
ACR20 response with ADA, ETA, and INF is of c54.871 (95% CI, c45,080–70,095), 
c80,598 (c64,288–c107.999), and c63,329 (c47,268c–c95,923), respectively. The 
incremental annual cost per additional patient who achieves ACR50 response with 
ADA, ETA, and INF is of c53,368 (c44,407–c66,828), c54,596 (c45,691–c67,813), 
and c93,072 (c65,451–c161,030), respectively. The incremental annual cost per addi-
tional patient who achieves ACR70 response with ADA, ETA, and INF is of c74,537 
(c59,759–c99,025), and c83,661 (c65,481–c115,815), c120,652 (c81,242–c34,319), 
respectively. CONCLUSIONS: The incremental cost per patient who achieves an 
ACR20, ACR50, and ACR70 response is lower with ADA, though quite similar to ETA, 
being with both (ADA and ETA) lower than with INF, in the Spanish setting.
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OBJECTIVES: To evaluate direct medical costs of treatment for osteoporotic fractures 
in Slovenia and Serbia from a public payer and patient perspective directly after fracture 
and up to 1 year follow-up. METHODS: A medical chart review, examining medical 
resources used to treat the 3 most common osteoporotic fractures (proximal femur, 
vertebral and distal radius) in the ﬁ rst year after the event. Collection of data from 1 
osteoporotic center in Slovenia and 3 in Serbia was carried out by local investigators 
between December 2009 and March 2010. The treatment costs for each fracture type 
from the public payer and patient perspective were calculated. The analysis was divided 
into 2 parts: intervention directly after the fracture (including cost of hospitalization, 
ambulatory visits, procedures, examinations, and medications) and follow-up for up to 
1 year after the event (including costs of hospitalization, outpatient visits, examinations, 
rehabilitation, medications and devices). RESULTS: A total of 240 patients aged >50 
years with low-trauma fractures occurring within 5 years before study initiation were 
included. Average annual costs of treatment of a proximal femur fracture in Slovenia 
were estimated at c4727 (costs directly after fracture = c4088 and follow-up period = 
c639) and in Serbia c3002 (c2359 and c642, respectively). The cost of treatment of a 
vertebral fracture was c4319 in Slovenia (c3762 and c557, respectively) and in Serbia 
c390 (c103 and c287, respectively). Treatment of the distal radius fracture was c1567 
in Slovenia (c1046 and c521, respectively) and in Serbia c163 (c57 and c106, respec-
tively). CONCLUSIONS: Treatment of proximal femur fractures vs. vertebral and distal 
radius fractures generated the highest costs. The treatment costs were signiﬁ cantly higher 
in Slovenia compared with Serbia. Large disparities between the costs of hospitalization 
in both countries were the major reason for the observed differences.
PMS30
MEDICINE TREATMENT COST OF RHEUMATOID ARTHRITIS BEFORE 
AND AFTER TREATMENT WITH BIOLOGICAL DRUGS
Roux I, Lubbe M, Burger JR, Lamprecht J
North-West University, Potchefstroom, South Africa
OBJECTIVES: To investigate the medicine treatment cost of rheumatoid arthritis (RA) 
before and after treatment with biological drugs in the private health care sector of 
South Africa. METHODS: A quantitative retrospective drug utilization review was 
performed on medicine claims data of a pharmacy beneﬁ t management company 
(PBM) in South Africa. Data for a four-year period (January 1, 2005 to December 31, 
